Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

Broad HIV-1 neutralization mediated by CD4-binding site antibodies

Abstract

We have identified several patient sera showing potent and broad HIV-1 neutralization. Using antibody adsorption and elution from selected gp120 variants, the neutralizing specificities of the two most broadly reactive sera were mapped to the primary receptor CD4–binding region of HIV-1 gp120. Novel antibodies to the CD4-binding site are elicited in some HIV-1–infected individuals, and new approaches to present this conserved region of gp120 to the immune system may result in improved vaccine immunogens.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Adsorption of sera with gp120WT and CD4-binding site mutant proteins.
Figure 2: Analysis of antibodies eluted from Env protein beads and after additional adsorption to enrich for CD4-binding site antibodies.

Similar content being viewed by others

References

  1. Haynes, B.F. & Montefiori, D.C. Expert Rev. Vaccines 5, 579–595 (2006).

    Article  CAS  Google Scholar 

  2. Burton, D.R. et al. Nat. Immunol. 5, 233–236 (2004).

    Article  CAS  Google Scholar 

  3. Mascola, J.R. et al. J. Infect. Dis. 173, 340–348 (1996).

    Article  CAS  Google Scholar 

  4. Wyatt, R. & Sodroski, J. Science 280, 1884–1888 (1998).

    Article  CAS  Google Scholar 

  5. Steimer, K.S., Scandella, C.J., Skiles, P.V. & Haigwood, N.L. Science 254, 105–108 (1991).

    Article  CAS  Google Scholar 

  6. Stamatos, N.M. et al. J. Virol. 72, 9656–9667 (1998).

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Dhillon, A.K. et al. J. Virol. 81, 6548–6552 (2007).

    Article  CAS  Google Scholar 

  8. Migueles, S.A. et al. Nat. Immunol. 3, 1061–1068 (2002).

    Article  CAS  Google Scholar 

  9. Thali, M. et al. J. Virol. 65, 5007–5012 (1991).

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Olshevsky, U. et al. J. Virol. 64, 5701–5707 (1990).

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Pantophlet, R. et al. J. Virol. 77, 642–658 (2003).

    Article  CAS  Google Scholar 

  12. Wyatt, R. et al. Nature 393, 705–711 (1998).

    Article  CAS  Google Scholar 

  13. Kwong, P.D. et al. Structure 8, 1329–1339 (2000).

    Article  CAS  Google Scholar 

  14. Parren, P.W. et al. J. Virol. 75, 8340–8347 (2001).

    Article  CAS  Google Scholar 

  15. Zhou, T. et al. Nature 445, 732–737 (2007).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This research was supported in part by the Intramural Research Program of the Vaccine Research Center and Division of Intramural Research, National Institute of Allergy and Infectious Diseases, US National Institutes of Health. G.M.S. and R.T.W. were supported in part by a grant from the Bill & Melinda Gates Foundation Grand Challenges initiative. R.T.W. also receives funding from the International AIDS Vaccine Initiative. We thank P. Kwong and G. Nabel for helpful suggestions; L. Kong for the core molecular surface figure; L. Chen (Vaccine Research Center) for providing the Fab fragment of F105, which was obtained from the laboratory of M. Posner (Dana Farber Cancer Institute); D. Burton (Scripps Research Institute) for mAb IgG1b12; H. Katinger (Polymun Scientific Inc.) for mAb 2G12; S. Zolla-Pazner (New York University School of Medicine) for mAb 447-52D; J. Sodroski and D. Gabuzda (Dana Farber Cancer Institute), J. Overbaugh (Fred Hutchinson Cancer Research Center), L. Morris (National Institute of Communicable Diseases), D. Montefiori (Duke University), J. Binley (Torrey Pines Institute for Molecular Sciences), L. Stamatatos (Seattle Biomedical Research Institute) and V. Polonis and F. McCutchan (U.S. Military Research Program) for providing virus isolates or functional Env plasmids; other members of the Wyatt laboratory who contributed ideas or reagents to the study; and B. Hartman and M. Cichanowski for help in preparation of the figures.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Richard T Wyatt.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Text and Figures

Supplementary Figs. 1 & 2, Supplementary Tables 1 & 2, Supplementary Methods (PDF 1114 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, Y., Migueles, S., Welcher, B. et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 13, 1032–1034 (2007). https://doi.org/10.1038/nm1624

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm1624

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing